Biomarin Pharmaceutical Inc at Barclays Global Healthcare Conference Transcript
As Gena mentioned, I'll start with just a few slides to orient you with the company, and then we'll -- I'll be brief so we can get into the Q&A. Briefly, forward-looking statements. I'll be making comments on BioMarin's future business prospects. So I definitely encourage you to review all of our disclosures in our SEC filings, including risk factors in our most recently filed Form 10-K.
I'll also comment on some non-GAAP financial measures. These are not meant to be reviewed in isolation or as a substitute for GAAP and are provided as supplemental information to highlight some of our operating performance.
So BioMarin is a best-in-class genetic disease company at an inflection point of transformative growth. Captured here are the 3 cornerstones to our investment thesis that I'll review with you briefly. It all starts with this solid, profitable IRA insulated and growing base business of mostly enzyme-based therapies that generate nearly $2 billion of revenue as well as positive operating cash flows.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
